Aim : Portal vein thrombosis (PVTT) is a life shortening complication for patients with liver cirrhosis (LC) accompanied with hepatocellular carcinoma (HCC). We investigated the therapeutic effect of selective transcatheter arterial embolisation with Lipiodol emulsion (Lp-TAE) on PVTT developed in patients with LC and HCC, and esophagogastric varices (EGV). Subjects and methods : Subjects consisted of 8 patients with LC and HCC, and PVTT. The causes of LC were HCV in 5, HBV in 2 and HCV+HBV in 1 patient. Mean age was 55.6±8.5 years old. Lp-TAE was targeted to hepatic arteries forming the “thread and streak sign.” Changes in the severity of EGV and liver function, and patient outcome were investigated. Results : The severity of EGV did not change after Lp-TAE. Liver functions estimated by Child-Pugh score deteriorated (from 6.63± 1.30 to 7.50±2.00). Mean life-span after Lp-TAE was 36.5 months. One, three and five year survival rates were 87.5%, 70% and 52.5%, respectively. The causes of death were hepatic failure in 2 and a complicating disease in 1. Conclusion : Lp-TAE for PVTT in patients with LC and HCC, and EGV dose not worsen EGV and may be effective in prolonging survival, especially in patients without severe liver dysfunction. Therapy for PVTT is the first choice in patients with EGV and HCC accompanied with PVTT.